InvestSMART

Kazia Therapeutics Limited (ASX: KZA) - Announcements

DELISTED - Current share price for KZA : $0.080

ASX company news and announcements for Kazia Therapeutics Limited (KZA) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Kazia Therapeutics Limited (KZA) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Kazia Therapeutics Limited (KZA), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Kazia Therapeutics Limited (KZA)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Kazia response to SEC comments letter 6 Apr 2022 9:04AM $1.095 $0.080 fallen by 92.69%
- Kazia to present at two conferences 21 Mar 2022 9:46AM $0.885 $0.080 fallen by 90.96%
- Change in substantial holding 2 Mar 2022 8:27AM $0.955 $0.080 fallen by 91.62%
- First patient into Cornell keto study 28 Feb 2022 9:44AM $0.975 $0.080 fallen by 91.79%
- Kazia Half Year Accounts and Appx 4D 23 Feb 2022 12:08PM $1.020 $0.080 fallen by 92.16%
- Notification regarding unquoted securities - KZA 1 Feb 2022 2:29PM $0.970 $0.080 fallen by 91.75%
- Quarterly Activities/Appendix 4C Cash Flow Report 31 Jan 2022 10:26AM $0.935 $0.080 fallen by 91.44%
- Kazia Corporate Deck 19 Jan 2022 11:19AM $1.135 $0.080 fallen by 92.95%
- Change of Director's Interest Notice 22 Dec 2021 9:42AM $1.090 $0.080 fallen by 92.66%
- Change of Director's Interest Notice * 3 21 Dec 2021 9:49AM $1.070 $0.080 fallen by 92.52%
- Change in substantial holding 17 Dec 2021 8:23AM $1.055 $0.080 fallen by 92.42%
- Issue of shares 15 Dec 2021 2:44PM $1.075 $0.080 fallen by 92.56%
- Kazia appoints Karen Krumeich as CFO 13 Dec 2021 9:28AM $1.140 $0.080 fallen by 92.98%
- Kazia releases final data from P2 paxalisib trial 3 Dec 2021 9:24AM $1.385 $0.080 fallen by 94.22%
- GBM Agile opens to paxalisib in Canada 29 Nov 2021 9:26AM $1.380 $0.080 fallen by 94.20%
- Notification of cessation of securities - KZA 24 Nov 2021 11:03AM $1.450 $0.080 fallen by 94.48%
- Notification regarding unquoted securities - KZA 16 Nov 2021 5:34PM $1.565 $0.080 fallen by 94.89%
- Kazia appoints John Friend as CMO 15 Nov 2021 9:21AM $1.550 $0.080 fallen by 94.84%
- Kazia enrols first patient to PNOC study 11 Nov 2021 8:34AM $1.550 $0.080 fallen by 94.84%
- Kazia AGM - Results of Meeting 10 Nov 2021 12:12PM $1.620 $0.080 fallen by 95.06%
- Chairman's Address to Shareholders 10 Nov 2021 9:43AM $1.575 $0.080 fallen by 94.92%
- Notification of cessation of securities - KZA 4 Nov 2021 9:48AM $1.570 $0.080 fallen by 94.90%
- Notification of cessation of securities - KZA 4 Nov 2021 9:46AM $1.570 $0.080 fallen by 94.90%
- Kazia enrols first patient to EVT801 Phase I clinical trial 4 Nov 2021 9:38AM $1.570 $0.080 fallen by 94.90%
- Quarterly Activities/Appendix 4C Cash Flow Report 29 Oct 2021 9:13AM $1.500 $0.080 fallen by 94.67%

176 - 200 of 476 results

Page 8 of 20

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.